What are ADC's

Our services

ADC Review
is made possible by:

NCT01335958 (Clinical Trial / DMUC5754A / Sofituzumab Vedotin)

Study Title
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer (NCT01335958)

Trial Description
This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A (Sofituzumab Vedotin) administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition:
    • Ovarian Cancer
    • Pancreatic Cancer
  • Interventions:
    • Drugs used in this trial
      • Drug: DMUC5754A (Sofituzumab Vedotin)
  • Phase: I
  • Enrollment: 77
  • Start: April 2011
  • Completion: February 2014
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 14, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar